NECTIN4×PD-L1 bispecific ADC / Dong-A - LARVOL DELTA

NECTIN4×PD-L1 bispecific antibody-drug conjugate integrating checkpoint blockade and targeted cytotoxicity for urothelial carcinoma and lung squamous cell carcinoma (AACR 2026) - "Background: The first-line approval of enfortumab vedotin plus pembrolizumab validates the clinical rationale for combining ADCs with ICIs... This NECTIN4×PD-L1 bispecific ADC integrates targeted cytotoxicity (NECTIN4) and checkpoint blockade (PD-L1) into a single therapeutic agent, rationally designed to provide catch-all activity against target and immune microenvironment heterogeneity in la/mUC and LUSC. The preclinical data support evaluation as an early-line therapeutic strategy that could complement or substitute separate ADC+ICI combinations."

ADC • Bispecific • Checkpoint block • Checkpoint inhibition • IO biomarker • Bladder Cancer • Genito-urinary Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer • NECTIN4